Zimbabwe has turned down a significant American health deal worth $367m (£272m) over five years over Washington's insistence on sensitive data.
This rejection was revealed after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative has since explained that the US was demanding access to genetic material for research and commercial gain but refused to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further dialogue to secure a deal acceptable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court suspended a related deal with the US following legal challenges were raised about the safety of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to boost openness and responsibility.
Based on statements, 16 nations in Africa have so far agreed to these new health pacts, representing more than $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no equivalent assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"In essence, our nation would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our citizens if a new disease outbreak emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining structures previously set up through the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This system is designed to guarantee that when a nation provides its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further discussions with our US partners on how future co-operation might be designed in a way that respects the sovereignty and interests of each country."
Health Experts Reaction
Medical experts stated it acknowledged the official position, but urged that talks need to persist since a large portion of the country's Aids initiatives relied on external financing.
"In cases where technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," it commented.
The situation highlights the complex tensions between receiving crucial international aid and safeguarding local interests in an increasingly interconnected world.